Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India

Table 3 Correlation of EZH2 mRNA expression with the clinicopathological factors of esophageal carcinoma patients

Clinicopathological parameters	No. of patients	EZH2 expression relative to β-Actin	p-value
Age
≥ 50	40	6.53 ± 1.4	0.595
< 50	12	6.61 ± 1.9
Sex
Male	31	6.47 ± 1.4	0.751
Female	21	6.66 ± 1.6
Classification
Locally advanced resectable	25	6.59 ± 1.5
Locally advanced unresectable	23	6.63 ± 1.6	0.532
Metastatic	4	5.79 ± 1.1
Dysphagia Grade
dys Gr1	1	6.34 ± 0
dys Gr2	18	6.31 ± 1.5
dys Gr3	21	6.96 ± 1.5	0.314
dys Gr4	11	6.41 ± 1.2
dys Gr5	1	3.83 ± 0
Location of Tumor
Upper third	7	6.28 ± 1.9
Middle third	24	6.67 ± 1.6	0.799
Lower third	21	6.51 ± 1.2
Smoking
Smoker	30	6.51 ± 1.3	0.803
Non-smoker	22	6.60 ± 1.7
Alcohol
Alcoholic	20	6.58 ± 1.6	0.94
Non-Alcoholic	32	6.53 ± 1.5
Tobacco
Tobacco Chewer	5	6.32 ± 1.2	0.78
Non-Tobacco Chewer	47	6.57 ± 1.5
Type
SCC	47	6.58 ± 1.5	0.609
Adeno	5	6.19 ± 0.8
Diet
Veg	28	6.33 ± 1.3	0.233
NonVeg	24	6.80 ± 1.6

ISSN: 1475-2867